At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,165 enrolled
Drug / intervention
Eplerenonedrug
Likely dose
Eplerenone 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DRUG USE INVESTIGATION OF SELARA(REGISTERED). TABLETS(AN INVESTIGATION FOR CHRONIC HEART FAILURE)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Nov 17, 2017·Updated Jul 11, 2023
In Brief
An observational study evaluating Eplerenone for Chronic Heart Failure. Completed, enrolled 1,165 participants across 1 site.
Detailed Summary
Secondary Data Collection Study; Safety And Effectiveness Of Selara Under Japanese Medical Practice
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedNov 2017
Primary CompletionJul 2020
TodayJul 2026
First PostedNov 17, 2017
Enrollment StartJul 5, 2017
Primary CompletionJul 15, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 8.6 years ago
Interventions
Eplerenonedrug
In adults, usually, administer the initial dose of 25 mg once daily according to the patient's serum potassium level and conditions, increase dosage up to 50 mg once daily after 4 week; patients with moderate renal impairment should start with 25 mg every other day and the maximum dosage should be 25 mg once daily. Also, dose should be reduced or interrupted according to serum potassium level and patient's conditions.